Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous ...

Vaccines are one of, if not THE most significant public health achievements. They played a pivotal role in reducing mortality from infectious diseases, once the leading causes of death. Routine ...

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment ...

About an hour after the closing bell, shares of Emergent were trading 6.4% higher, at $7.31. The company's shares ended the day's regular session at $6.87, a gain of 3.7%.

Emergent BioSolutions (EBS) has secured a $51.9M contract modification award to deliver CNJ-016 to the Administration for Strategic Preparedness and Response (A ...

Investing.com -- Emergent BioSolutions Inc (NYSE: EBS) stock rose 6.3% after the company announced a contract modification to deliver additional doses of its smallpox vaccination complication ...

Doctors groups and public health organizations are suing the U.S. government over the decision to stop recommending COVID-19 ...

The 19th-century power struggle between the Sikhs, the British, and the Afghans shaped the political landscape of the time.